An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases (opens ClinicalTrials.gov)
- Sponsor
- National Human Genome Research Institute (NHGRI)
- Enrolment
- 30
- Started
- 2026-10-27
- Last update
- 2026-10-30
Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
Interventions: ManNAc